Signant Health
06/30/2022 | News release | Distributed by Public on 06/30/2022 13:37
ASCP 2022: Scientific Posters Compilation
Signant's psychiatry experts and CNS thought leaders presented scientific posters at the American Society of Clinical Psychopharmacology's 2022 annual meeting hosted in Arizona from May 31-June 3.
Two of the posters presented original research important to understanding factors that influence data quality in clinical trials: the relationship between baseline severity of negative symptoms and end of treatment improvement in schizophrenia studies, as well as rapid recruitment in acute schizophrenia studies and associated data quality concerns. Topics also included findings from a phase 3 study on an adjunctive treatment for Major Depressive Disorder, and the validity of a new, shorter form of the PANSS scale to measure treatment sensitivity in pediatric psychopharmacology studies.
Browse through each poster below and meet our experts.
[Link][Link][Link][Link]Signant Health
Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently generate quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 20 years, over 400 sponsors and CROs of all sizes - including all of Top 20 pharma - have trusted Signant Health solutions for remote and site-based eCOA, eConsent, IRT, supply chain management, and data quality analytics.